Susan L Baldwin

Summary

Affiliation: Infectious Disease Research Institute
Country: USA

Publications

  1. ncbi Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
  2. ncbi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
  3. ncbi Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
  4. ncbi The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
  5. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
  6. ncbi Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
  7. ncbi Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
  8. ncbi Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
  9. ncbi Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
  10. ncbi Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay
    Lance K Ching
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    J Immunol Methods 373:54-62. 2011

Collaborators

Detail Information

Publications14

  1. ncbi Intradermal immunization improves protective efficacy of a novel TB vaccine candidate
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    Vaccine 27:3063-71. 2009
    ..This highlights the need to explore different routes of immunization based on the adjuvant formulations used...
  2. ncbi Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, United States
    Vaccine 27:5956-63. 2009
    ....
  3. ncbi Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions
    Susan L Baldwin
    Infectious Disease Research Institute, 1124 Columbia St, Suite 400, Seattle, WA 98104, USA
    Vaccine 29:644-9. 2011
    ..Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model...
  4. ncbi The importance of adjuvant formulation in the development of a tuberculosis vaccine
    Susan L Baldwin
    Infectious Disease Research Institute, Seattle, WA 98104, USA
    J Immunol 188:2189-97. 2012
    ..These results highlight the importance of properly formulating subunit vaccines with effective adjuvants for use against tuberculosis...
  5. ncbi Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, Seattle WA 98104, USA
    J Immunol 181:7948-57. 2008
    ..This study identified numerous novel human T cell Ags suitable to be included in subunit vaccines against tuberculosis...
  6. ncbi Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant
    Rhea N Coler
    Preclinical Biology, Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 6:e16333. 2011
    ....
  7. ncbi Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA
    AAPS PharmSciTech 13:498-506. 2012
    ....
  8. ncbi Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, USA
    J Infect Dis 207:1242-52. 2013
    ....
  9. ncbi Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions
    Christopher B Fox
    Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, WA 98104, United States
    Vaccine 29:9563-72. 2011
    ....
  10. ncbi Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay
    Lance K Ching
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    J Immunol Methods 373:54-62. 2011
    ..Overall, the QuantiGene platform is reliable, reproducible, and sensitive. These agonists have the potential to be used as adjuvant components in vaccines against various pathogens...
  11. ncbi A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis
    Sylvie Bertholet
    Infectious Disease Research Institute, 1124 Columbia Street, Suite 400, Seattle, WA 98104, USA
    Sci Transl Med 2:53ra74. 2010
    ....
  12. ncbi A synthetic adjuvant to enhance and expand immune responses to influenza vaccines
    Rhea N Coler
    Infectious Disease Research Institute, Seattle, Washington, United States of America
    PLoS ONE 5:e13677. 2010
    ..These results suggest that synthetic TLR4 adjuvants can enhance the magnitude and quality of protective immunity induced by influenza vaccines...
  13. ncbi Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines
    Christopher B Fox
    Infectious Disease Research Institute, Seattle, Washington, USA
    Clin Vaccine Immunol 19:1633-40. 2012
    ..Emulsion dose titration in the absence of formulated GLA caused some reduction in humoral and cellular immune responses compared to those with the 2% squalene emulsion dose...
  14. ncbi Adjuvant solution for pandemic influenza vaccine production
    Christopher H Clegg
    TRIA Bioscience Corp, Seattle, WA 98104, USA
    Proc Natl Acad Sci U S A 109:17585-90. 2012
    ..Innate signaling pathways that amplify priming of Th1 CD4 T cells will likely improve vaccine performance against future outbreaks of lethal pandemic flu...